Based on the CONSENSUS trial, what is the relative risk of death at 1 year in the enalapril group compared to the placebo?

Based on the CONSENSUS trial, what is the relative risk of death at 1 year in the enalapril group compared to the placebo?

• A. 0.16
• B. 0.59
• C. 0.52
• D. 0.69

Answer: (D)

The relative risk of death at 1 year in the enalapril group compared to the placebo group, as derived from the CONSENSUS trial, indicates a significant reduction in mortality associated with the use of enalapril in patients with heart failure. The value of 0.69 represents a 31% relative reduction in the risk of death when patients were treated with enalapril compared to those who received placebo. This finding underscores the efficacy of enalapril in improving survival rates among patients with severe heart failure, highlighting its importance as a cornerstone therapy in this population. The other values, while reflecting various degrees of risk reduction, do not accurately represent the data from the trial for this specific comparison. The correct understanding of the 0.69 relative risk emphasizes the meaningful impact of angiotensin-converting enzyme (ACE) inhibitors like enalapril in the management of heart failure and their role in improving patient outcomes.

The relative risk of death at 1 year in the enalapril group compared to the placebo group, as derived from the CONSENSUS trial, indicates a significant reduction in mortality associated with the use of enalapril in patients with heart failure. The value of 0.69 represents a 31% relative reduction in the risk of death when patients were treated with enalapril compared to those who received placebo. This finding underscores the efficacy of enalapril in improving survival rates among patients with severe heart failure, highlighting its importance as a cornerstone therapy in this population.

The other values, while reflecting various degrees of risk reduction, do not accurately represent the data from the trial for this specific comparison. The correct understanding of the 0.69 relative risk emphasizes the meaningful impact of angiotensin-converting enzyme (ACE) inhibitors like enalapril in the management of heart failure and their role in improving patient outcomes.